Severe respiratory illnesses in newborns are a leading cause of pediatric death worldwide, resulting in over 1 million deaths annually; 99% of these deaths occur in low-to middle-income countries.
for infants in respiratory distress.
However, infants with more serious respiratory illnesses need more advanced therapy, traditionally provided with a mechanical ventilator. In many settings, current treatment options for newborns with these severe illnesses are too expensive, require highly skilled operators, and fail during power outages that are common in the developing world.
Product
We aim to develop high-quality, low-cost, low-power, and easy-to-use respiratory equipment for patients in emerging markets. Our patent-pending NeoVent is a one-connection add-on to existing bCPAP setups to provide the next level of care: noninvasive bilevel pressure ventilation. Our easy-touse design has only one moving piece and does not require continuous electricity. As with a traditional ventilator, the clinician can use NeoVent to set two independent pressure levels and the rate cycling between them.
We anticipate the NeoVent can be manufactured for less than 1/100th the manufacturing cost of traditional ventilators.
Next Steps
We have completed preclinical studies demonstrating device efficacy and are currently preparing to launch our first-in-human NeoVent safety study, followed by a larger study of efficacy. After clinical validation, we plan to wholesale the device as a oneconnection add-on to companies with developed distribution channels and customer bases that are selling complementary respiratory equipment. In addition, we anticipate partnering with international medical device distributors to conduct direct sales in target geographic locations.
After launching direct sales in countries where the device has been studied in clinical trials, we will subsequently scale in additional emerging markets.
Company Purpose
A dvanced Innovative Medical Technologies (AIM Tech) seeks to develop high-quality, low-cost, low-power, and easy-to-use medical equipment that will enable clinicians to provide excellent medical care in resourcelimited settings. Our initial product, NeoVent, is an easy-to-use respiratory device for achieving noninvasive pressure ventilation at a fraction of the cost of existing options.
Problem We Want to Solve
Severe respiratory illnesses in newborns are a leading cause of pediatric death worldwide, resulting in over 1 million deaths annually; 99% of these deaths occur in low-to middle-income countries. 1 The remaining 30% of infants with more severe respiratory illnesses often need advanced respiratory therapy. These infants, with weaker musculature and less mature lungs, benefi t from noninvasive ventilation such as bilevel positive airway pressure or nasal intermittent positive pressure ventilation. 6 These treatments can be provided using expensive Adjusting the air-fl ow rate alters the rate at which the fl oat fi lls, which in turn sets the cycles/minute.
By utilizing pipes with diff ering distances between
the proximal and distal holes, diff erent pressure gradients (high pressure level-low pressure level)
can be delivered to the patient. Thus, the valve aff ects a controllable dual pressure waveform. 
Competition and Diff erentiation
To our knowledge, NeoVent could be the fi rst low-cost, nonelectric, noninvasive dual pressure ventilator to reach the market. NeoVent is a patent-pending technology. 
Market Analysis

Market Trends and Key Demand Drivers
The NeoVent capitalizes on several key trends in our target markets. In emerging markets, most major medical-device manufacturers have begun investing in developing "context-appropriate" medical devices that are low cost, low power, and easy to use. Globally, pulmonologists and respiratory therapists are increasingly selecting simple, noninvasive respiratory therapies over traditional invasive mechanical ventilation therapies. 10,11
Business Model
Revenue Model
In emerging markets, we plan to sell NeoVent to hospitals and other healthcare providers, wholesaling the device via medical-device distributors and strategic reseller partners.
Marketing and Sales Strategy
AIM Tech's strategy is fi rst to market NeoVent as an add-on to existing bCPAP setups in emerging Because NeoVent is a one-connection add-on to basic respiratory equipment such as bubble CPAP setups, we can utilize the existing sales and distribution channels in place at these manufacturers by developing strategic resale partnerships. Selling via these companies is the most efficient way for us to bring NeoVent to market in the near future.
Hospitals and Healthcare Networks:
We intend to sell to these institutions in select geographic locations by using local distributors who will also provide service and technical support. We anticipate our first sales will take place in the countries where we will launch our safety and efficacy studies. Subsequently, we plan to scale throughout Southeast Asia and Africa. In both cases we will leverage our existing relationships with in-country accelerators and partners. Many hospitals and clinics in the developing world obtain the majority of their devices through local distributors; therefore, we plan to contract with multiple local distributors in our target markets, both directly and through international medical-device distributors. Our device will be a complementary sale to more basic respiratory equipment sold by these distributors.
Individual Healthcare Providers: After we have established market traction, we plan to further scale the device to more remote emerging market settings, selling to individual providers such as skilled birth attendants and community health workers. To reach these groups, we plan to leverage partnerships with nongovernmental organizations (NGOs) that support individual community health providers and other maternal-neonatal health initiatives. These NGO partnerships will help us access these large user bases, and assist in providing training, service, and support. We believe that through these partnerships, we can unlock a large, untapped market with revenue potential that has not been captured in the global respiratory therapy market size and growth estimates mentioned above, thus greatly increasing our impact. These regions have unmet needs that represent a significant market opportunity for our device. For example, India alone has 2.1 million skilled birth attendants. In preparation for the initial contracting, we are currently being advised by several firms on material selection and other design and manufacturing decisions. We are also in the process of selecting a GMP-compliant manufacturing partner to assist in future device production.
Traction and Company Status
Company Next Steps
Business Development and Sales in Emerging Mar-
kets: After receiving results from the safety study and initial results from the physiologic safety and efficacy trials, we plan to select a strategic resale partner. Our ideal partner will have existing market penetration in our target markets; provide training, service, and support for our device; and commit to growing sales of NeoVent. In parallel, we will hire in-country sales staff for our initial pilot markets who will be responsible for initiating pilots and establishing relationships with local distributors. 
